Dual-Epigenetic CHOP Misses PTCL Endpoints

Company Peking Union Medical College Hospital (Academic) Event Type Peer-Reviewed Publication (Investigator-Led Phase 3 Trial) Modality Hypomethylating Agent + HDAC Inhibitor + Chemotherapy (Azacitidine + Chidamide + CHOP) Asset AC-CHOP (Azacitidine, Chidamide, CHOP) Target DNA Methyltransferases / Class I and IIb Histone Deacetylases Disease Area…